価格表

在庫・価格 : 2025年02月08日 00時37分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
BNP Fragment, EIA Kit (12×8tests)
データシート
BI-20852W BMCバイオメディカ
BIOMEDICA Medizinprodukte GmbH
1 kit ¥137,000
(未発注)
追加

在庫・価格 : 2025年02月08日 00時37分 現在

BNP Fragment, EIA Kit (12×8tests)

  • 商品コード:BI-20852W
  • メーカー:BMC
  • 包装:1kit
  • 価格: ¥137,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Sliwa K et al. Spectrum of cardiac disease in maternity in a low-resource cohort in South Africa. Heart 2014 Dec;100(24):1967-74
Sliwa K et al
2014/01/01
PubMed
2 Rost NS et al. Brain natriuretic peptide predicts functional outcome in ischemic stroke. Stroke 2012 Feb;43(2):441-5
Rost NS et al
2012/01/01
PubMed
3 Meadows CA et al. Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension. Chest 2011 May;139(5):994-1002
Meadows CA et al
2011/01/01
PubMed
4 El-Khuffash AF et al. Troponin T, N-terminal pro natriuretic peptide and a patent ductus arteriosus scoring system predict death before discharge or neurodevelopmental outcome at 2 years in preterm infants. Arch. Dis. Child. Fetal Neonatal Ed. 2011 Mar;96
El-Khuffash AF et al
2011/01/01
PubMed
5 McDonald VM et al. Multidimensional assessment of older people with asthma and COPD: clinical management and health status. Age Ageing 2011 Jan;40(1):42-9
McDonald VM et al
2011/01/01
PubMed
6 Ala-Kopsala M et al. Characterization of molecular forms of N-terminal B-type natriuretic peptide in vitro. Clin. Chem. 2010 Dec;56(12):1822-9
Ala-Kopsala M et al
2010/01/01
PubMed
7 Patrianakos AP et al. Restrictive filling pattern is associated with increased humoral activation and impaired exercise capacity in dilated cardiomyopathy. Eur. J. Heart Fail. 2004 Oct;6(6):735-43
Patrianakos AP et al
2004/01/01
PubMed
8 Jarai R et al. Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. Eur. Heart J. 2005 Feb;26(3):250-6
Jarai R et al
2005/01/01
PubMed
9 H端lsmann M et al. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur. Heart J. 2002 Jun;23(11):886-91
H端lsmann M et al
2002/01/01
PubMed
10 Hammerer-Lercher A et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin. Chem. 2004 Jul;50(7):1174-83
Hammerer-Lercher A et al
2004/01/01
PubMed
11 Brueckmann M et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005 Jul;112(4):527-34
Brueckmann M et al
2005/01/01
PubMed
12 Berger R et al. Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Eur. J. Clin. Invest. 2005 Jan;35(1):24-31
Berger R et al
2005/01/01
PubMed
13 Mir TS et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 2003 Oct;112(4):896-9
Mir TS et al
2003/01/01
PubMed
14 Stanek B et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J. Am. Coll. Cardiol. 2001 Aug;38(2):436-42
Stanek B et al
2001/01/01
PubMed
15 Berger R et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002 May;105(20):2392-7
Berger R et al
2002/01/01
PubMed
16 Ellinor PT et al. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J. Am. Coll. Cardiol. 2005 Jan;45(1):82-6
Ellinor PT et al
2005/01/01
PubMed
17 Molhoek SG et al. Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy. Heart 2004 Jan;90(1):97-8
Molhoek SG et al
2004/01/01
PubMed
18 Sin DD et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest 2007 Jan;131(1):156-63
Sin DD et al
2007/01/01
PubMed
19 Kremastinos DT et al. NT-proBNP levels and diastolic dysfunction in beta-thalassaemia major patients. Eur. J. Heart Fail. 2007 May;9(5):531-6
Kremastinos DT et al
2007/01/01
PubMed
20 Seferian KR et al. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin. Chem. 2008 May;54(5):866-73
Seferian KR et al
2008/01/01
PubMed
21 Parthenakis FI et al. NT-proBNP response to dobutamine stress echocardiography predicts left ventricular contractile reserve in dilated cardiomyopathy. Eur. J. Heart Fail. 2008 May;10(5):475-81
Parthenakis FI et al
2008/01/01
PubMed
22 Dimitroulas T et al. Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford) 2008 Nov;47(11):1682-5
Dimitroulas T et al
2008/01/01
PubMed
23 Kuznetsova T et al. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail 2009 Mar;2(2):105-12
Kuznetsova T et al
2009/01/01
PubMed
24 Hammerer-Lercher A et al. Clinical value of a competitive NT-proBNP enzyme immunoassay compared to the Roche NT-proBNP platform. Clin. Chem. Lab. Med. 2009;47(10):1305-8
Hammerer-Lercher A et al
2009/01/01
PubMed
25 Long AC et al. Comparison of pleural fluid N-terminal pro-brain natriuretic peptide and brain natriuretic-32 peptide levels. Chest 2010 Jun;137(6):1369-74
Long AC et al
2010/01/01
PubMed
26 Gonz叩lez A et al. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension 2010 Jun;55(6):1418-24
Gonz叩lez A et al
2010/01/01
PubMed
27 Kuznetsova T et al. Prognostic value of left ventricular diastolic dysfunction in a general population. J Am Heart Assoc 2014 Apr;3(3):e000789
Kuznetsova T et al
2014/01/01
PubMed
28 Laflamme MH et al. Parathyroid hormone is associated with the LV mass after aortic valve replacement. Heart 2014 Dec;100(23):1859-64
Laflamme MH et al
2014/01/01
PubMed
29 Mebazaa A et al. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. Circulation 2014 Jul;130(5):410-8
Mebazaa A et al
2014/01/01
PubMed
30 Liu Q et al. Function of N-terminal pro-brain natriuretic peptide in Takayasu arteritis disease monitoring. J. Rheumatol. 2014 Aug;41(8):1683-8
Liu Q et al
2014/01/01
PubMed
31 Clerico A et al. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin. Chem. 2000 Oct;46(10):1529-34
Clerico A et al
2000/01/01
PubMed
32 Mir TS et al. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002 Dec;110(6):e76
Mir TS et al
2002/01/01
PubMed
33 Mueller T et al. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin. Chem. 2003 Jun;49(6 Pt 1):976-
Mueller T et al
2003/01/01
PubMed
34 Magnusson M et al. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004 Aug;27(8):1929-35
Magnusson M et al
2004/01/01
PubMed
35 Kupari M et al. Is the pregnancy hormone relaxin an important player in human heart failure? Eur. J. Heart Fail. 2005 Mar;7(2):195-8
Kupari M et al
2005/01/01
PubMed
36 Hermann-Arnhof KM et al. N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure. Clin. Chem. 2005 Jan;51(1):138-43
Hermann-Arnhof KM et al
2005/01/01
PubMed
37 Flevari P et al. Coronary and peripheral blood flow changes following biventricular pacing and their relation to heart failure improvement. Europace 2006 Jan;8(1):44-50
Flevari P et al
2006/01/01
PubMed
38 Thackray SD et al. N-terminal brain natriuretic peptide as a screening tool for heart failure in the pacemaker population. Eur. Heart J. 2006 Feb;27(4):447-53
Thackray SD et al
2006/01/01
PubMed
39 Manuchehri AM et al. The effect of thyroid dysfunction on N-terminal pro-B-type natriuretic peptide concentrations. Ann. Clin. Biochem. 2006 May;43(Pt 3):184-8
Manuchehri AM et al
2006/01/01
PubMed
40 Kjekshus JK et al. Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure. Eur. J. Heart Fail. 2009 Aug;11(8):771-8
Kjekshus JK et al
2009/01/01
PubMed
41 Gali竪 N et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
Gali竪 N et al
2017/01/01
PubMed
42 Clerico A et al. Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J. Endocrinol. Invest. 2001 Jan;24(1):24-30
Clerico A et al
2001/01/01
PubMed
43 Ellinor PT et al. Reduced apelin levels in lone atrial fibrillation. Eur. Heart J. 2006 Jan;27(2):222-6
Ellinor PT et al
2006/01/01
PubMed
44 Hassan S et al. Does Ramadan Fasting Affect Hydration Status and Kidney Function in CKD Patients? Ann. Nutr. Metab. 2018;72(3):241-247
Hassan S et al
2018/01/01
PubMed
45 Ji C et al. Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors. Clin Cancer Res 2019 Aug;25(15):4735-4748
Ji C et al
2019/01/01
PubMed
  • No.: 1
  • 文献情報:
    Sliwa K et al. Spectrum of cardiac disease in maternity in a low-resource cohort in South Africa. Heart 2014 Dec;100(24):1967-74
    Sliwa K et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Rost NS et al. Brain natriuretic peptide predicts functional outcome in ischemic stroke. Stroke 2012 Feb;43(2):441-5
    Rost NS et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Meadows CA et al. Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension. Chest 2011 May;139(5):994-1002
    Meadows CA et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    El-Khuffash AF et al. Troponin T, N-terminal pro natriuretic peptide and a patent ductus arteriosus scoring system predict death before discharge or neurodevelopmental outcome at 2 years in preterm infants. Arch. Dis. Child. Fetal Neonatal Ed. 2011 Mar;96
    El-Khuffash AF et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    McDonald VM et al. Multidimensional assessment of older people with asthma and COPD: clinical management and health status. Age Ageing 2011 Jan;40(1):42-9
    McDonald VM et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Ala-Kopsala M et al. Characterization of molecular forms of N-terminal B-type natriuretic peptide in vitro. Clin. Chem. 2010 Dec;56(12):1822-9
    Ala-Kopsala M et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Patrianakos AP et al. Restrictive filling pattern is associated with increased humoral activation and impaired exercise capacity in dilated cardiomyopathy. Eur. J. Heart Fail. 2004 Oct;6(6):735-43
    Patrianakos AP et al
    2004/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Jarai R et al. Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. Eur. Heart J. 2005 Feb;26(3):250-6
    Jarai R et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    H端lsmann M et al. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur. Heart J. 2002 Jun;23(11):886-91
    H端lsmann M et al
    2002/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Hammerer-Lercher A et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin. Chem. 2004 Jul;50(7):1174-83
    Hammerer-Lercher A et al
    2004/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Brueckmann M et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005 Jul;112(4):527-34
    Brueckmann M et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Berger R et al. Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Eur. J. Clin. Invest. 2005 Jan;35(1):24-31
    Berger R et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Mir TS et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 2003 Oct;112(4):896-9
    Mir TS et al
    2003/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Stanek B et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J. Am. Coll. Cardiol. 2001 Aug;38(2):436-42
    Stanek B et al
    2001/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Berger R et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002 May;105(20):2392-7
    Berger R et al
    2002/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Ellinor PT et al. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J. Am. Coll. Cardiol. 2005 Jan;45(1):82-6
    Ellinor PT et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Molhoek SG et al. Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy. Heart 2004 Jan;90(1):97-8
    Molhoek SG et al
    2004/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Sin DD et al. Effects of nocturnal noninvasive mechanical ventilation on heart rate variability of patients with advanced COPD. Chest 2007 Jan;131(1):156-63
    Sin DD et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Kremastinos DT et al. NT-proBNP levels and diastolic dysfunction in beta-thalassaemia major patients. Eur. J. Heart Fail. 2007 May;9(5):531-6
    Kremastinos DT et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Seferian KR et al. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin. Chem. 2008 May;54(5):866-73
    Seferian KR et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Parthenakis FI et al. NT-proBNP response to dobutamine stress echocardiography predicts left ventricular contractile reserve in dilated cardiomyopathy. Eur. J. Heart Fail. 2008 May;10(5):475-81
    Parthenakis FI et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Dimitroulas T et al. Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford) 2008 Nov;47(11):1682-5
    Dimitroulas T et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 23
  • 文献情報:
    Kuznetsova T et al. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail 2009 Mar;2(2):105-12
    Kuznetsova T et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 24
  • 文献情報:
    Hammerer-Lercher A et al. Clinical value of a competitive NT-proBNP enzyme immunoassay compared to the Roche NT-proBNP platform. Clin. Chem. Lab. Med. 2009;47(10):1305-8
    Hammerer-Lercher A et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 25
  • 文献情報:
    Long AC et al. Comparison of pleural fluid N-terminal pro-brain natriuretic peptide and brain natriuretic-32 peptide levels. Chest 2010 Jun;137(6):1369-74
    Long AC et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 26
  • 文献情報:
    Gonz叩lez A et al. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension 2010 Jun;55(6):1418-24
    Gonz叩lez A et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 27
  • 文献情報:
    Kuznetsova T et al. Prognostic value of left ventricular diastolic dysfunction in a general population. J Am Heart Assoc 2014 Apr;3(3):e000789
    Kuznetsova T et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 28
  • 文献情報:
    Laflamme MH et al. Parathyroid hormone is associated with the LV mass after aortic valve replacement. Heart 2014 Dec;100(23):1859-64
    Laflamme MH et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 29
  • 文献情報:
    Mebazaa A et al. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. Circulation 2014 Jul;130(5):410-8
    Mebazaa A et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 30
  • 文献情報:
    Liu Q et al. Function of N-terminal pro-brain natriuretic peptide in Takayasu arteritis disease monitoring. J. Rheumatol. 2014 Aug;41(8):1683-8
    Liu Q et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 31
  • 文献情報:
    Clerico A et al. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin. Chem. 2000 Oct;46(10):1529-34
    Clerico A et al
    2000/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 32
  • 文献情報:
    Mir TS et al. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002 Dec;110(6):e76
    Mir TS et al
    2002/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 33
  • 文献情報:
    Mueller T et al. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin. Chem. 2003 Jun;49(6 Pt 1):976-
    Mueller T et al
    2003/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 34
  • 文献情報:
    Magnusson M et al. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004 Aug;27(8):1929-35
    Magnusson M et al
    2004/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 35
  • 文献情報:
    Kupari M et al. Is the pregnancy hormone relaxin an important player in human heart failure? Eur. J. Heart Fail. 2005 Mar;7(2):195-8
    Kupari M et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 36
  • 文献情報:
    Hermann-Arnhof KM et al. N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure. Clin. Chem. 2005 Jan;51(1):138-43
    Hermann-Arnhof KM et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 37
  • 文献情報:
    Flevari P et al. Coronary and peripheral blood flow changes following biventricular pacing and their relation to heart failure improvement. Europace 2006 Jan;8(1):44-50
    Flevari P et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 38
  • 文献情報:
    Thackray SD et al. N-terminal brain natriuretic peptide as a screening tool for heart failure in the pacemaker population. Eur. Heart J. 2006 Feb;27(4):447-53
    Thackray SD et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 39
  • 文献情報:
    Manuchehri AM et al. The effect of thyroid dysfunction on N-terminal pro-B-type natriuretic peptide concentrations. Ann. Clin. Biochem. 2006 May;43(Pt 3):184-8
    Manuchehri AM et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 40
  • 文献情報:
    Kjekshus JK et al. Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure. Eur. J. Heart Fail. 2009 Aug;11(8):771-8
    Kjekshus JK et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 41
  • 文献情報:
    Gali竪 N et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
    Gali竪 N et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 42
  • 文献情報:
    Clerico A et al. Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J. Endocrinol. Invest. 2001 Jan;24(1):24-30
    Clerico A et al
    2001/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 43
  • 文献情報:
    Ellinor PT et al. Reduced apelin levels in lone atrial fibrillation. Eur. Heart J. 2006 Jan;27(2):222-6
    Ellinor PT et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 44
  • 文献情報:
    Hassan S et al. Does Ramadan Fasting Affect Hydration Status and Kidney Function in CKD Patients? Ann. Nutr. Metab. 2018;72(3):241-247
    Hassan S et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 45
  • 文献情報:
    Ji C et al. Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors. Clin Cancer Res 2019 Aug;25(15):4735-4748
    Ji C et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed